Janssen Pharmaceuticals, Inc. Completes Divestiture of U.S. License Rights to NUCYNTA(R) (tapentadol), NUCYNTA(R) ER (tapentadol) extended-release tablets and NUCYNTA(R) (tapentadol) Oral Solution to

Article

JPI's licensed U. commercialization rights to NUCYNTA (tapentadol), NUCYNTA ER (tapentadol) extended-release tablets, and NUCYNTA (tapentadol) oral solution from Grunenthal GmbH were assigned to Depomed.

PRESS RELEASE

TITUSVILLE, N.J., April 2, 2015 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (JPI) today announced it has completed the divestiture of its U.S. license rights to NUCYNTA

®

(tapentadol), NUCYNTA

®

ER (tapentadol) extended-release tablets and NUCYNTA

®

(tapentadol) oral solution to Depomed for $1.05 billion.

JPI's licensed U.S. commercialization rights to NUCYNTA

®

(tapentadol), NUCYNTA

®

ER (tapentadol) extended-release tablets and NUCYNTA

®

(tapentadol) oral solution from Grunenthal GmbH were assigned to Depomed. JPI will retain license rights to NUCYNTA

®

(tapentadol), NUCYNTA

®

ER (tapentadol) extended-release tablets and NUCYNTA

®

(tapentadol) oral solution in Canada, Japan, and a number of other countries outside the United States.

About NUCYNTA

®

NUCYNTA

®

(tapentadol) and NUCYNTA

®

ER (tapentadol) extended-release tablets are opioid-based medicines used for treatment of pain. NUCYNTA

®

(tapentadol) is indicated for the management of moderate-to-severe acute pain in adults. NUCYNTA

®

ER (tapentadol) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate and of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Full product labeling including Boxed Warnings for NUCYNTA

®

and NUCYNTA

®

ER is available at www.Nucynta.com. NUCYNTA

®

(tapentadol) oral solution is an approved oral form of tapentadol that has not been launched.

Related Videos
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
Image credit: New Africa | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image Credit: Pixel-Shot | stock.adobe.com
Pharmacist holding medicine box and capsule pack in pharmacy drugstore. -- Image credit: I Viewfinder | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.